Dr. Eggener on active surveillance: “There’s superb long-term outcomes”
"It’s an important topic to debate,” says Scott E. Eggener, MD.
In this video, Scott Eggener, MD, discusses the key points of the debate, “What is the Preferred Approach for Low Risk Prostate Cancer?” being presented today at the 2021 Society of Urologic Oncology Annual Meeting. Eggener is a Bruce and Beth White Family professor of surgery and radiology, vice chair of the section of urology, and director of the High Risk and Advanced Prostate Cancer Clinic at the University of Chicago Medical Center in Chicago, Illinois.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
